

Robert G Gish

List of Publications by Citations

Source: <https://exaly.com/author-pdf/625151/robert-g-gish-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

267
papers

12,441
citations

60
h-index

105
g-index

328
ext. papers

14,210
ext. citations

5.6
avg, IF

6.17
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 267 | A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , 2006 , 354, 1001-10 | 59.2 | 1146 |
| 266 | Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004 , 127, 485-92 | 13.3 | 378 |
| 265 | American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. <i>Gastroenterology</i> , 2015 , 148, 221-244.e3 | 13.3 | 335 |
| 264 | A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2001 , 33, 424-32 | 11.2 | 330 |
| 263 | Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. <i>Gastroenterology</i> , 2007 , 133, 1437-44 | 13.3 | 283 |
| 262 | Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998 , 27, 213-22 | 11.2 | 279 |
| 261 | Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. <i>Hepatology</i> , 1996 , 24, 6-9 | 11.2 | 252 |
| 260 | Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. <i>Journal of Clinical Investigation</i> , 1991 , 88, 270-81 | 15.9 | 244 |
| 259 | Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. <i>Hepatology</i> , 1999 , 29, 1581-6 | 11.2 | 241 |
| 258 | Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , 2006 , 44, 915-24 | 11.2 | 231 |
| 257 | A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. <i>Gastroenterology</i> , 2005 , 129, 1198-209 | 13.3 | 219 |
| 256 | RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017 , 9, | 17.5 | 216 |
| 255 | Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3069-75 | 2.2 | 202 |
| 254 | Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. <i>Gastroenterology</i> , 2003 , 125, 107-16 | 13.3 | 190 |
| 253 | Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. <i>Journal of Infectious Diseases</i> , 2005 , 191, 825-9 | 7 | 186 |
| 252 | Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. <i>Gastroenterology</i> , 2003 , 124, 925-32 | 13.3 | 182 |
| 251 | Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015 , 121, 47-58 | 10.8 | 175 |

| | | | |
|-----|---|------|-----|
| 250 | A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003 , 38, 34-41 | 11.2 | 171 |
| 249 | Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. <i>Hepatology</i> , 2007 , 46, 324-9 | 11.2 | 166 |
| 248 | Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 6413-8 | 11.5 | 164 |
| 247 | Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. <i>Hepatology</i> , 2013 , 57, 881-9 | 11.2 | 159 |
| 246 | Keratin 8 mutations in patients with cryptogenic liver disease. <i>New England Journal of Medicine</i> , 2001 , 344, 1580-7 | 59.2 | 156 |
| 245 | Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2060-3 | 0.7 | 151 |
| 244 | Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. <i>Liver Transplantation</i> , 2006 , 12, S128-36 | 4.5 | 131 |
| 243 | A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. <i>Hepatology</i> , 2004 , 40, 747-55 | 11.2 | 127 |
| 242 | Is chronic hepatitis B being undertreated in the United States?. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 377-83 | 4 | 126 |
| 241 | Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. <i>Journal of General Virology</i> , 2004 , 85, 811-820 | 4.9 | 124 |
| 240 | Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012 , 12, 341-53 | 25.5 | 111 |
| 239 | Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 16-22 | 3.4 | 109 |
| 238 | Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). <i>Journal of Virology</i> , 2002 , 76, 6131-7 | 6.6 | 106 |
| 237 | Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015 , 121, 97-108 | 10.8 | 105 |
| 236 | Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. <i>Hepatology</i> , 2002 , 35, 922-9 | 11.2 | 101 |
| 235 | The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. <i>Value in Health</i> , 2008 , 11, 527-38 | 3.3 | 100 |
| 234 | Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. <i>Hepatology</i> , 1999 , 30, 833-8 | 11.2 | 98 |
| 233 | Hepatitis C virus as a systemic disease: reaching beyond the liver. <i>Hepatology International</i> , 2016 , 10, 415-23 | 8.8 | 95 |

| | | | |
|-----|---|------|----|
| 232 | Chronic hepatitis B: what should be the goal for new therapies?. <i>Antiviral Research</i> , 2013 , 98, 27-34 | 10.8 | 95 |
| 231 | Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. <i>Gastroenterology</i> , 2005 , 129, 494-503 | 13.3 | 93 |
| 230 | Changing nomenclature for PBC: From RirrhosisPto RholangitisP <i>Hepatology</i> , 2015 , 62, 1620-2 | 11.2 | 92 |
| 229 | Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007 , 45, 569-78 | 11.2 | 88 |
| 228 | Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 8-13 | 5.1 | 82 |
| 227 | Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. <i>Journal of Hepatology</i> , 2005 , 43, 60-6 | 13.4 | 79 |
| 226 | Entecavir versus other oral antiviral drugs for chronic hepatitis B. <i>The Cochrane Library</i> , 2018 , | 5.2 | 78 |
| 225 | A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <i>Hepatology</i> , 2002 , 36, 1253-8 | 11.2 | 76 |
| 224 | Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 941-6; quiz e68 | 6.9 | 74 |
| 223 | Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. <i>Clinics in Liver Disease</i> , 2015 , 19, 309-23 | 4.6 | 73 |
| 222 | Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. <i>Transplantation</i> , 1998 , 66, 956-62 | 1.8 | 72 |
| 221 | Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. <i>Current Gastroenterology Reports</i> , 2014 , 16, 365 | 5 | 71 |
| 220 | Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005 , 129, 494-503 | 13.3 | 71 |
| 219 | Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. <i>Journal of Virological Methods</i> , 2001 , 98, 153-9 | 2.6 | 71 |
| 218 | T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1-7 | 11.6 | 70 |
| 217 | Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 581-7 | 4.5 | 70 |
| 216 | Are infectious agents involved in primary biliary cirrhosis? A PCR approach. <i>Journal of Hepatology</i> , 1999 , 31, 664-71 | 13.4 | 70 |
| 215 | Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1521-5 | 4 | 69 |

| | | | |
|-----|---|------|----|
| 214 | Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 799-802 | 6.9 | 69 |
| 213 | Rate of natural disease progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2003 , 38, 307-14 | 13.4 | 69 |
| 212 | Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. <i>Liver Transplantation</i> , 2006 , 12, S105-7 | 4.5 | 68 |
| 211 | Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006 , 12, S95-7 | 4.5 | 66 |
| 210 | Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. <i>Liver International</i> , 2007 , 27, 1394-401 | 7.9 | 63 |
| 209 | Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016 , 122, 2512-23 | 6.4 | 62 |
| 208 | Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. <i>Liver Transplantation</i> , 2006 , 12, S114-6 | 4.5 | 60 |
| 207 | Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017 , 6, 350-362 | 2.3 | 58 |
| 206 | Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. <i>Journal of Medical Virology</i> , 2004 , 73, 516-21 | 19.7 | 58 |
| 205 | Changing nomenclature for PBC: from PcirrhosisPto PcholangitisP. <i>Gastroenterology</i> , 2015 , 149, 1627-9 | 13.3 | 56 |
| 204 | Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Journal of Hepatology</i> , 2015 , 63, 1285-7 | 13.4 | 55 |
| 203 | A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018 , 67, 1127-1131 | 11.2 | 51 |
| 202 | Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 578-85 | 4 | 51 |
| 201 | Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 173-85 | 4.2 | 51 |
| 200 | Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. <i>Journal of Medical Virology</i> , 2006 , 78, 1296-303 | 19.7 | 50 |
| 199 | Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. <i>Journal of Virology</i> , 1998 , 72, 2738-44 | 6.6 | 49 |
| 198 | Model for end-stage liver disease (MELD) exception guidelines. <i>Liver Transplantation</i> , 2006 , 12, S85-7 | 4.5 | 48 |
| 197 | Hepatocellular carcinoma: overcoming challenges in disease management. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 252-61 | 6.9 | 48 |

| | | |
|-----|---|---------|
| 196 | Chronic hepatitis B: current testing strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 666-766.9 | 48 |
| 195 | Optimization for the detection of hepatitis C virus antigens in the liver. <i>Journal of Hepatology</i> , 1994 , 20, 143-7 | 13.4 48 |
| 194 | RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31 | 11.2 47 |
| 193 | The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 155-61 | 3 46 |
| 192 | Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. <i>World Journal of Gastroenterology</i> , 2012 , 18, 498-506 | 5.6 45 |
| 191 | Chronic hepatitis B infection. <i>Clinics in Liver Disease</i> , 2012 , 16, 347-69 | 4.6 44 |
| 190 | Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 52-62 | 18.8 43 |
| 189 | A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2718-23 | 0.7 43 |
| 188 | Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007 , 47, 51-9 | 13.4 41 |
| 187 | Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. <i>Journal of Virological Methods</i> , 2003 , 110, 29-35 | 2.6 41 |
| 186 | Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma?. <i>Clinics in Liver Disease</i> , 2016 , 20, 563-80 | 4.6 40 |
| 185 | Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019 , 70, 1008-1015 | 13.4 40 |
| 184 | Immunosuppression in Patients with Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2014 , 13, 235-244 | 1 38 |
| 183 | Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. <i>Cancer Biomarkers</i> , 2012 , 11, 161-71 | 3.8 38 |
| 182 | Global HBV burden: guesstimates and facts. <i>Hepatology International</i> , 2018 , 12, 315-329 | 8.8 37 |
| 181 | Model for end-stage liver disease (MELD) exception for polycystic liver disease. <i>Liver Transplantation</i> , 2006 , 12, S110-1 | 4.5 37 |
| 180 | Long-term follow-up after liver transplantation in patients with hepatic iron overload. <i>Liver Transplantation</i> , 1999 , 5, 369-74 | 37 |
| 179 | Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naïve hepatitis C patients. <i>Journal of Hepatology</i> , 2010 , 52, 32-8 | 13.4 36 |

| | | | |
|-----|--|------|----|
| 178 | The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008 , 4, 19-33 | 3.8 | 35 |
| 177 | Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. <i>Pharmacoeconomics</i> , 2007 , 25, 963-77 | 4.4 | 34 |
| 176 | Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1222-9 | 4 | 33 |
| 175 | Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1429-1438 | 0.7 | 32 |
| 174 | Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2014 , 20, 1454-61 | 4.5 | 30 |
| 173 | Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. <i>Journal of Hepatology</i> , 1995 , 22, 257-62 | 13.4 | 30 |
| 172 | Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e57-9 | 2.4 | 29 |
| 171 | The NS5A replication complex inhibitors: difference makers?. <i>Clinics in Liver Disease</i> , 2011 , 15, 627-39 | 4.6 | 28 |
| 170 | De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. <i>American Journal of Transplantation</i> , 2003 , 3, 1413-7 | 8.7 | 28 |
| 169 | Management of hepatitis C virus in special populations: patient and treatment considerations. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 311-8 | 6.9 | 27 |
| 168 | Changing Nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1536-8 | 0.7 | 26 |
| 167 | Portal vein thrombosis. <i>Clinics in Liver Disease</i> , 2015 , 19, 199-221 | 4.6 | 26 |
| 166 | Chronic hepatitis B: a critical appraisal of current approaches to therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 233-48 | 6.9 | 26 |
| 165 | Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6295-304 | 5.6 | 26 |
| 164 | Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 238-47 | 4 | 25 |
| 163 | PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg Journal of Hepatology, 2019 , 70, e51-e52 | 13.4 | 24 |
| 162 | PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019 , 70, e32 | 13.4 | 24 |
| 161 | One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. <i>Journal of Virological Methods</i> , 2013 , 193, 531-5 | 2.6 | 24 |

| | | | |
|-----|--|------|----|
| 160 | The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015 , 21, 873-80 | 4.5 | 24 |
| 159 | A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 905-8 | 3.4 | 23 |
| 158 | Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 1240-52 | 6.1 | 23 |
| 157 | Autoimmune liver disease. Current standards, future directions. <i>Clinics in Liver Disease</i> , 2001 , 5, 287-314 | 4.6 | 23 |
| 156 | Changing nomenclature for PBC: from PcirrhosisPto PcholangitisP. <i>Gut</i> , 2015 , 64, 1671-2 | 19.2 | 22 |
| 155 | Clinical trial results of new therapies for HBV: implications for treatment guidelines. <i>Seminars in Liver Disease</i> , 2005 , 25 Suppl 1, 29-39 | 7.3 | 22 |
| 154 | Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 707-716 | 3.8 | 21 |
| 153 | Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017 , 77, 1263-1280 | 12.1 | 21 |
| 152 | Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 397-408 | 1.6 | 21 |
| 151 | Current treatment and future directions in the management of chronic hepatitis B viral infection. <i>Clinics in Liver Disease</i> , 2005 , 9, 541-65, v | 4.6 | 20 |
| 150 | Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 219-27 | 0.7 | 20 |
| 149 | An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , 2021 , 74, 607-626 | 11.2 | 20 |
| 148 | Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016 , 15, 237-244 | 1 | 20 |
| 147 | Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia. <i>JIMD Reports</i> , 2016 , 25, 87-94 | 1.9 | 19 |
| 146 | Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016 , 22, 1356-66 | 4.5 | 19 |
| 145 | Cellular mechanics of germ band retraction in Drosophila. <i>Developmental Biology</i> , 2013 , 384, 205-13 | 3.1 | 19 |
| 144 | Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 3073-7 | 4 | 19 |
| 143 | Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e40-51 | 3.4 | 19 |

| | | | |
|-----|---|------|----|
| 142 | The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. <i>PLoS ONE</i> , 2015 , 10, e0140870 | 3.7 | 19 |
| 141 | Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2015 , 2, e000032 | 3.9 | 18 |
| 140 | Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4644-51 | 5.6 | 18 |
| 139 | A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009 , 3, 480-9 | 8.8 | 18 |
| 138 | Hepatitis B in liver transplant recipients. <i>Liver Transplantation</i> , 2006 , 12, S54-64 | 4.5 | 18 |
| 137 | Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016 , 64, S390-S391 | 13.4 | 18 |
| 136 | Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016 , 64, 326-332 | 13.4 | 17 |
| 135 | RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. <i>Antiviral Therapy</i> , 2011 , 16, 547-54 | 1.6 | 17 |
| 134 | To "be" or not to "be": that is the question. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1948-52 | 0.7 | 17 |
| 133 | Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S91-2 | 4.5 | 17 |
| 132 | Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017 , 66, S27 | 13.4 | 16 |
| 131 | Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines. <i>Clinics in Liver Disease</i> , 2019 , 23, 383-399 | 4.6 | 16 |
| 130 | Elevated expression of tyrosine kinase DDR2 in primary biliary cirrhosis. <i>Autoimmunity</i> , 2002 , 35, 521-9 | 3 | 16 |
| 129 | Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 2595-601 | 4 | 16 |
| 128 | Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 511-20 | 3.5 | 15 |
| 127 | Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naïve patients treated with entecavir. <i>Antiviral Therapy</i> , 2013 , 18, 691-8 | 1.6 | 15 |
| 126 | Hepatocellular carcinoma: molecular and genomic guideline for the clinician. <i>Clinics in Liver Disease</i> , 2011 , 15, 307-21, vii-x | 4.6 | 15 |
| 125 | Changing nomenclature for PBC: From Cirrhosis To Cholangitis. <i>Digestive and Liver Disease</i> , 2015 , 47, 924-6 | 3.3 | 14 |

| | | | |
|-----|---|------|----|
| 124 | Changing Nomenclature for PBC: From P^{C} irrhosis to P^{C} holangitis? <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1867-9 | 6.9 | 14 |
| 123 | A clinical assessment of Wilson disease in patients with concurrent liver disease. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 267-73 | 3 | 14 |
| 122 | Improving outcomes for patients with chronic hepatitis B. <i>Current Gastroenterology Reports</i> , 2007 , 9, 14-22 | 5 | 14 |
| 121 | Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 2006 , 12, S108-9 | 4.5 | 14 |
| 120 | Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 743-753 | 18.8 | 14 |
| 119 | United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board. <i>Clinical Transplantation</i> , 2015 , 29, 513-22 | 3.8 | 13 |
| 118 | Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 784-9 | 3.4 | 13 |
| 117 | Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2013 , 18, 229-35 | 1.6 | 13 |
| 116 | Hepatitis B treatment: Current best practices, avoiding resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 3, S14-9 | 2.8 | 13 |
| 115 | Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 17-21 | 3.4 | 12 |
| 114 | Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. <i>Clinical Transplantation</i> , 2011 , 25, E152-62 | 3.8 | 12 |
| 113 | Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 275-85 | 2.9 | 12 |
| 112 | A review of liver transplantation for the dentist and guidelines for dental management. <i>Special Care in Dentistry</i> , 1993 , 13, 74-80 | 1.7 | 12 |
| 111 | Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 293-9 | 0.7 | 12 |
| 110 | Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. <i>Liver International</i> , 2018 , 38, 451-457 | 7.9 | 12 |
| 109 | Views of US Voters on Compensating Living Kidney Donors. <i>JAMA Surgery</i> , 2016 , 151, 710-6 | 5.4 | 11 |
| 108 | Current treatment guidelines for chronic hepatitis B and their applications. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 773-83 | 3 | 11 |
| 107 | Genotyping and genomic sequencing in clinical practice. <i>Clinics in Liver Disease</i> , 2007 , 11, 761-95, viii | 4.6 | 11 |

| | | | |
|-----|--|------|----|
| 106 | Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1089-1097 | 3.4 | 11 |
| 105 | Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. <i>Hepatology International</i> , 2016 , 10, 624-31 | 8.8 | 11 |
| 104 | Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 887-897 | 4.7 | 11 |
| 103 | Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. <i>Clinical Liver Disease</i> , 2018 , 12, 5-11 | 2.2 | 10 |
| 102 | Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. <i>Liver International</i> , 2007 , 27, 1111-8 | 7.9 | 10 |
| 101 | Model for end-stage liver disease (MELD) exception for cystic fibrosis. <i>Liver Transplantation</i> , 2006 , 12, S98-9 | 4.5 | 10 |
| 100 | Model for end-stage liver disease (MELD) exception for hepatic encephalopathy. <i>Liver Transplantation</i> , 2006 , 12, S102-4 | 4.5 | 10 |
| 99 | Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance. <i>Journal of Hepatology</i> , 2016 , 64, S398 | 13.4 | 10 |
| 98 | Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019 , 14, e0220612 | 3.7 | 9 |
| 97 | Treating hepatitis C: the state of the art. <i>Gastroenterology Clinics of North America</i> , 2004 , 33, S1-9 | 4.4 | 9 |
| 96 | Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 350-361 | 3.4 | 9 |
| 95 | Hepatocellular carcinoma (HCC): current and evolving therapies. <i>IDrugs: the Investigational Drugs Journal</i> , 2008 , 11, 198-203 | | 9 |
| 94 | Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. <i>BMJ Open</i> , 2019 , 9, e028248 | 3 | 8 |
| 93 | Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization. <i>Hepatology</i> , 2013 , 57, 1675-6 | 11.2 | 8 |
| 92 | Customizing the management of chronic hepatitis B virus infection. <i>Seminars in Liver Disease</i> , 2007 , 27 Suppl 1, 9-17 | 7.3 | 8 |
| 91 | Transmission of hepatitis B virus through allotransplantation. <i>Liver Transplantation</i> , 1996 , 2, 161-4 | | 8 |
| 90 | Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. <i>BMJ Open Gastroenterology</i> , 2019 , 6, e000256 | 3.9 | 7 |
| 89 | High rate of core promoter and precore mutations in patients with chronic hepatitis B. <i>Hepatology International</i> , 2015 , 9, 209-17 | 8.8 | 7 |

| | | | |
|----|--|------|---|
| 88 | Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009 , 29, 375-83 | 7.9 | 7 |
| 87 | Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006 , 12, S88-90 | 4.5 | 7 |
| 86 | Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome. <i>Liver Transplantation</i> , 2006 , 12, S93-4 | 4.5 | 7 |
| 85 | Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. <i>Liver Transplantation</i> , 2006 , 12, S124-7 | 4.5 | 7 |
| 84 | Future directions in the treatment of patients with chronic hepatitis C virus infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999 , 13, 57-62 | | 7 |
| 83 | A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-16 | 0.7 | 7 |
| 82 | Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. <i>Translational Cancer Research</i> , 2013 , 2, 460-471 | 0.3 | 7 |
| 81 | Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2021 , | 19.2 | 7 |
| 80 | More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e392-e399 | 3 | 7 |
| 79 | Chronic hepatitis B virus in the Philippines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 945-52 | 4 | 6 |
| 78 | Markov modeling in hepatitis B screening and linkage to care. <i>Theoretical Biology and Medical Modelling</i> , 2017 , 14, 11 | 2.3 | 6 |
| 77 | Hepatocellular carcinoma: locoregional and targeted therapies. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 599-610 | 4.4 | 6 |
| 76 | Acute liver failure in adults: an evidence-based management protocol for clinicians. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 161-212 | 0.7 | 6 |
| 75 | A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population. <i>Journal of Hepatology</i> , 2017 , 66, S265 ^{13.4} | | 5 |
| 74 | 1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2010 , 52, S388-S389 | 13.4 | 5 |
| 73 | Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. <i>Liver Transplantation</i> , 2006 , 12, S117-8 | 4.5 | 5 |
| 72 | GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. <i>Pediatric Research</i> , 1999 , 45, 795-8 | 3.2 | 5 |
| 71 | Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 1-24 | 0.7 | 5 |

| | | | |
|----|--|------|---|
| 70 | Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2016 , 14, 41-56 | 5.5 | 4 |
| 69 | Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. <i>Liver Transplantation</i> , 2006 , 12, S112-3 | 4.5 | 4 |
| 68 | Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. <i>Liver Transplantation</i> , 2006 , 12, S122-3 | 4.5 | 4 |
| 67 | Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007 , 37, S67-78 | 5.1 | 4 |
| 66 | Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 339-44 | 4.4 | 4 |
| 65 | Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease. <i>Liver Transplantation</i> , 2005 , 11, 366 | 4.5 | 4 |
| 64 | Treatment of chronic hepatitis B: new antiviral therapies. <i>Current Gastroenterology Reports</i> , 1999 , 1, 20-6 | 5 | 4 |
| 63 | Is there a serological difference between men and women with primary biliary cirrhosis?. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2482-2486 | 0.7 | 4 |
| 62 | Recent developments in the treatment of chronic hepatitis B virus infection. <i>Expert Opinion on Investigational Drugs</i> , 1995 , 4, 95-115 | 5.9 | 4 |
| 61 | Normal alkaline phosphatase levels are dependent on race/ethnicity: NationalGEP Health and Nutrition Examination Survey data. <i>BMJ Open Gastroenterology</i> , 2020 , 7, | 3.9 | 4 |
| 60 | Sofosbuvir/Ledipasvir without Ribavirin in the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016 , 64, S815-S816 | 13.4 | 4 |
| 59 | Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017 , 4, e000158 | 3.9 | 3 |
| 58 | Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAi) Therapy Based on HBsAg Epitope Profile Analysis. <i>Journal of Hepatology</i> , 2016 , 64, S602 | 13.4 | 3 |
| 57 | Medical interventions associated with HBV reactivation: Common and less common. <i>Clinical Liver Disease</i> , 2015 , 5, 32-34 | 2.2 | 3 |
| 56 | Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 733-7 | 3 | 3 |
| 55 | Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. <i>AIDS Research and Therapy</i> , 2011 , 8, 29 | 3 | 3 |
| 54 | Model for end-stage liver disease (MELD) exception for severe pruritus. <i>Liver Transplantation</i> , 2006 , 12, S119 | 4.5 | 3 |
| 53 | Model for end-stage liver disease (MELD) exception small-for-size syndrome. <i>Liver Transplantation</i> , 2006 , 12, S120-1 | 4.5 | 3 |

| | | | |
|----|--|------|---|
| 52 | Calcium compartmentation and exchange rates in primary hepatocyte culture. <i>Analytical Biochemistry</i> , 1990 , 187, 187-96 | 3.1 | 3 |
| 51 | Epidemiology and Natural History of Chronic Hepatitis B Virus Infection 2018 , 63-89 | | 3 |
| 50 | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. <i>Clinics in Liver Disease</i> , 2019 , 23, 487-492 | 4.6 | 2 |
| 49 | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. <i>Clinics in Liver Disease</i> , 2019 , 23, 493-509 | 4.6 | 2 |
| 48 | Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. <i>Journal of Hepatology</i> , 2017 , 66, S257-S258 | 13.4 | 2 |
| 47 | Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients. <i>BMJ Open Gastroenterology</i> , 2015 , 2, e000030 | 3.9 | 2 |
| 46 | Hepatocellular Carcinoma: Current Questions and Future Directions. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 182-5 | 0.7 | 2 |
| 45 | Hepatitis D Virus: A Call to Screening. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 647-86 | 0.7 | 2 |
| 44 | Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2016 , 73-84 | 0 | 2 |
| 43 | Point of Care Diagnostic Testing for Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2020 , 19, 245-253 | 1 | 2 |
| 42 | Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. <i>Journal of Immigrant and Minority Health</i> , 2021 , 23, 1267-1279 | 2.2 | 2 |
| 41 | Geographic regions with high prevalence of nonalcoholic steatohepatitis-related hepatic fibrosis are also observed to demonstrate high prevalence of metabolic disease risk factors and low consumption of fruits and vegetables. <i>Clinical Nutrition Experimental</i> , 2020 , 30, 15-26 | 2 | 1 |
| 40 | Hepatitis B Core Antibody: Role in Clinical Practice in 2020. <i>Current Hepatology Reports</i> , 2020 , 19, 254-265 | | 1 |
| 39 | Identification of recombinant strains in HCV genotype 1 and 3: Is it needed?. <i>Liver International</i> , 2018 , 38, 958 | 7.9 | 1 |
| 38 | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. <i>Clinics in Liver Disease</i> , 2019 , 23, 511-519 | 4.6 | 1 |
| 37 | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. <i>Clinics in Liver Disease</i> , 2019 , 23, 521-534 | 4.6 | 1 |
| 36 | Diagnosis of chronic hepatitis B and the implications of viral variants and mutations. <i>American Journal of Medicine</i> , 2008 , 121, S12-21 | 2.4 | 1 |
| 35 | Chronic Hepatitis B Viral Infection 2112-2138 | | 1 |

| | | | |
|----|--|------|---|
| 34 | Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2007 , 1, 45-52. | 4.3 | 1 |
| 33 | Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy. <i>Liver Transplantation</i> , 2006 , 12, S100-1 | 4.5 | 1 |
| 32 | Studying the treatment of chronic hepatitis B viral infection in special populations. <i>Methods in Molecular Medicine</i> , 2004 , 96, 465-98 | | 1 |
| 31 | Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 679-689 | 0.7 | 1 |
| 30 | Risk Factors and Treatment for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2006 , 2, 477-478 | 0.7 | 1 |
| 29 | HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 292-295 | 0.7 | 1 |
| 28 | Monotherapy vs multiple-drug therapy: the experts debate. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 3, S20-4 | 2.8 | 1 |
| 27 | Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 10, 374-382 | 5.2 | 1 |
| 26 | We Are All Africans: A Highly Personal Migratory View of the History of Hepatitis B. <i>Clinical Liver Disease</i> , 2020 , 16, 24-33 | 2.2 | 1 |
| 25 | Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. <i>American Journal of Medicine</i> , 2021 , 134, 882-892 | 2.4 | 1 |
| 24 | Medical therapies to extend survival in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 1-14; quiz 15 | 0.6 | 1 |
| 23 | Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 2 p preceding 4-15 | 0.6 | 1 |
| 22 | Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11 Suppl 5, 1-22; quiz 2 p following p22 | 0.6 | 1 |
| 21 | Hepatitis B virus diagnostics: anything new? 2020 , 220-230 | | 0 |
| 20 | Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 146-148 | 6.9 | 0 |
| 19 | Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.. <i>Hepatology</i> , 2021 , | 11.2 | 0 |
| 18 | Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. <i>Hepatology Research</i> , 2021 , 51, 156-165 | 5.1 | 0 |
| 17 | Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. <i>Current Therapeutic Research</i> , 2020 , 93, 100594 | 2.4 | |

- 16 Chronic Hepatitis B Viral Infection **2016**, 387-391
- 15 HCV In At Risk Populations: Who Can be Treated and How?. *Current Hepatitis Reports*, **2012**, 11, 1-9
- 14 Investigation and diagnostic pathways **2013**, 48-64
- 13 The new epidemiology of hepatitis B in the United States. *Current Hepatitis Reports*, **2009**, 8, 3-9
- 12 Entecavir. *Drugs*, **2006**, 66, 1623-1624 12.1
- 11 Hepatitis B in liver transplant recipients as a special model of antiviral drug development. *Methods in Molecular Medicine*, **2004**, 96, 319-41
- 10 Variation in antibody reactivity to the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. *Viral Immunology*, **1993**, 6, 49-54 1.7
- 9 Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. *Gastroenterology and Hepatology*, **2010**, 6, 1-16 0.7
- 8 Delta virus infection: epidemiology and initiatives to intercept it. *Gastroenterology and Hepatology*, **2013**, 9, 589-91 0.7
- 7 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing. *Open Forum Infectious Diseases*, **2020**, 7, S562-S562 1
- 6 Current developments in the treatment of hepatitis and hepatobiliary disease. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 511-2 0.6
- 5 Letter to the editor.. *Hepatology*, **2022**, 11.2
- 4 Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis **2019**, 14, e0220612
- 3 Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis **2019**, 14, e0220612
- 2 Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis **2019**, 14, e0220612
- 1 Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis **2019**, 14, e0220612